More Company News

Hutchison China MediTech

Strategic partnership with Inmagene for drug candidate portfolio for immunological diseases
11 Jan 2021Read More

Hutchison China MediTech

China approval of surufatinib in epNET
30 Dec 2020Read More

Hutchison China MediTech

Initiation of rolling NDA submission for surufatinib in NETs
29 Dec 2020Read More

Hutchison China MediTech

Ground breaking ceremony for Shanghai manufacturing plant
08 Dec 2020Read More

Hutchison China MediTech

US$100m equity investment by CPP Investments
17 Nov 2020Read More

Hutchison China MediTech

HMPL-689 clinical data to be presented at ASH 2020
05 Nov 2020Read More

Hutchison China MediTech

Surufatinib Phase III data in NETs at ESMO 2020 and Publication in The Lancet Oncology
20 Sep 2020Read More

Hutchison China MediTech

Acceptance of second China NDA for surufatinib in pNET
17 Sep 2020Read More

Hutchison China MediTech

Initiation of global fruquintinib FRESCO-2 Phase III in mCRC
04 Sep 2020Read More

Hutchison China MediTech

Initiation of HMPL-453 China Phase II in advanced intrahepatic cholangiocarcinoma
03 Sep 2020Read More

1 2 3 4 … 7
Return to Hutchison China MediTech
© 2019-21 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).